| Primary information |
|---|
| ID | antitb_1221 |
| Peptide Name | PK34 |
| Sequence | PRVIETKVHGREVTGLARNVSEENVDRLAKRWIK |
| N-terminal Modification | Free |
| C-terminal Modification | Free |
| Chemical Modification | None |
| Linear/ Cyclic | Linear |
| Length | 34 |
| Chirality | L |
| Nature | Cationic |
| Source | Synthetic |
| Origin | Searched and selected from mycobacteriophage genome sequences |
| Species | Mycobacterium tuberculosis |
| Strain | Mycobacterium tuberculosis H37Rv strain (ATCC 27294 |
| Inhibition Concentartion | MIC = 50 μg/ml |
| In vitro/In vivo | Both |
| Cell Line | Murine macrophage-like J774A.1 |
| Inhibition Concentartion | NA |
| Cytotoxicity | NA |
| In vivo Model | Four-week-old female BALB/c mice |
| Lethal Dose | Dose of 20 mg (5×10−6 mol)/kg BW/d, PK34 had co |
| Immune Response | Inhibits the proinflammatory factor (IFN-γ, TNF-α, MCP-1, IL-6, IL-10, IL-12) production of macrophage cells induced by TDM. |
| Mechanism of Action | Cell wall disruption |
| Target | trehalose-6,6=-dimycolate (TDM) |
| Combination Therapy | None |
| Other Activities | None |
| Pubmed ID | 23603838 |
| Year of Publication | 2013 |
| 3-D Structure |  View in Jmol or Download Structure |